Source:http://linkedlifedata.com/resource/pubmed/id/15920913
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-5-30
|
| pubmed:abstractText |
Standard dose docetaxel is burdened by severe toxicity. Weekly schedules have been shown to be active as standard scheme with reduced side effects. In 20-30% of elderly patients (pts) the classic 6-week schedule induces grade 3/4 fatigue and other cumulative toxicities. We carried out this safety study in order to evaluate whether a modified weekly docetaxel schedule would improve the toxicity profile. Twenty-one untreated elderly (> or = 70 years) pts suffering from metastatic breast cancer were enrolled in the study. Pts were treated with a weekly dose of 35 mg/m2 docetaxel for 6 weeks, followed by a 2-week rest. Further cycles were performed with this modified schedule: docetaxel days 1, 8 and 15 every 29 days. All pts received at least the first cycle (6 weeks). A total of 261 doses were delivered. No toxic deaths occurred. The toxicity was mild: we recorded 1 episode of grade 3 neutropenia and severe asthenia in only 2 pts (10%). We recorded an overall response rate of 33% (1 CR, 6 PR). Our data showed a reduced incidence of severe asthenia (2/21), obtained with a light modification of a weekly docetaxel schedule.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1120-009X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
242-6
|
| pubmed:dateRevised |
2009-8-4
|
| pubmed:meshHeading |
pubmed-meshheading:15920913-Age Factors,
pubmed-meshheading:15920913-Aged,
pubmed-meshheading:15920913-Bone Neoplasms,
pubmed-meshheading:15920913-Breast Neoplasms,
pubmed-meshheading:15920913-Dose-Response Relationship, Drug,
pubmed-meshheading:15920913-Drug Administration Schedule,
pubmed-meshheading:15920913-Female,
pubmed-meshheading:15920913-Follow-Up Studies,
pubmed-meshheading:15920913-Geriatric Assessment,
pubmed-meshheading:15920913-Humans,
pubmed-meshheading:15920913-Liver Neoplasms,
pubmed-meshheading:15920913-Lung Neoplasms,
pubmed-meshheading:15920913-Lymphatic Metastasis,
pubmed-meshheading:15920913-Maximum Tolerated Dose,
pubmed-meshheading:15920913-Neoplasm Metastasis,
pubmed-meshheading:15920913-Neoplasm Staging,
pubmed-meshheading:15920913-Prospective Studies,
pubmed-meshheading:15920913-Risk Assessment,
pubmed-meshheading:15920913-Skin Neoplasms,
pubmed-meshheading:15920913-Survival Analysis,
pubmed-meshheading:15920913-Taxoids,
pubmed-meshheading:15920913-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
|
| pubmed:affiliation |
Unità Operativa Complessa di Oncologia Medica, Azienda Ospedaliera Universitaria G. Martino Policlinico Messina Via Consolare Valeria, Gazzi, 98125 Messina, Italy. maisano@supereva.it
|
| pubmed:publicationType |
Journal Article
|